# SLC6A11

## Overview
The SLC6A11 gene encodes the protein solute carrier family 6 member 11, commonly known as the GABA transporter 3 (GAT-3). This protein is a member of the solute carrier family 6 and functions as a transmembrane transporter. It plays a critical role in the central nervous system by facilitating the reuptake of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) from the synaptic cleft into glial cells. This process is essential for maintaining synaptic balance and preventing excessive neuronal excitability. GAT-3 operates as a sodium-dependent transporter, utilizing the sodium gradient to drive the uptake of GABA, thereby modulating synaptic transmission and ensuring neurotransmitter homeostasis (Pramod2013SLC6; Eulenburg2010Neurotransmitter). The gene's clinical significance is underscored by its association with various neurological disorders, including epilepsy and anxiety, due to its pivotal role in GABAergic neurotransmission (Hu2023Association).

## Structure
The SLC6A11 gene encodes the GABA transporter 3 (GAT-3), a member of the solute carrier family 6, which is involved in the transport of the inhibitory neurotransmitter GABA across cell membranes. The protein structure of SLC6A11 is characterized by 12 transmembrane helices, a common feature among neurotransmitter transporters in the SLC6 family (Pramod2013SLC6). These helices form a 5 + 5 helical architecture, where transmembrane segments 1-5 and 6-10 create two antiparallel pentahelical bundles, with transmembrane segments 11 and 12 playing a regulatory role (Pramod2013SLC6).

The primary binding site of SLC6A11 is located between transmembrane helices 1, 3, 6, 8, and 10, similar to the prokaryotic transporter LeuT. This site is composed of three subpockets (A, B, and C), each contributing to ligand binding and specificity (Colas2020Toward). The protein also features a unique residue in transmembrane helix 10, which may be a p-helix signature, distinguishing it from other subgroups within the SLC6 family (Colas2020Toward).

Post-translational modifications such as glycosylation and phosphorylation are likely to influence the function and localization of SLC6A11, although specific details on these modifications are not provided in the context (Pramod2013SLC6).

## Function
The SLC6A11 gene encodes the GABA transporter 3 (GAT3), which is primarily expressed in glial cells within the central nervous system. GAT3 is involved in the reuptake of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, from the synaptic cleft into glial cells. This process is crucial for regulating extracellular GABA levels and maintaining synaptic balance, thereby preventing excessive neuronal excitability (Pramod2013SLC6; Eulenburg2010Neurotransmitter).

GAT3 operates as a sodium-dependent transporter, utilizing the sodium gradient to facilitate the uptake of GABA into cells. This electrogenic transport mechanism is essential for terminating GABAergic signaling and maintaining low tonic concentrations of GABA outside synapses (Kristensen2011SLC6; Zhou2013GABA). The transporter is localized to GABAergic synapses, indicating its role in modulating synaptic transmission and ensuring proper neurotransmitter homeostasis (Pramod2013SLC6).

In healthy human cells, GAT3's activity is vital for preventing GABA-mediated overinhibition, which can lead to neurological issues such as seizures. The absence of GAT3 function, as observed in knockout models, results in increased susceptibility to seizures, highlighting its importance in maintaining normal neuronal function (Eulenburg2010Neurotransmitter).

## Clinical Significance
Mutations in the SLC6A11 gene, which encodes the GABA transporter GAT-3, are associated with various neurological disorders. These mutations can impair the transporter's function, leading to disrupted GABAergic neurotransmission, which is crucial for maintaining the balance of inhibitory and excitatory signals in the brain. Such disruptions can contribute to conditions like epilepsy, anxiety, and depression (Hu2023Association).

The SLC6A11 gene has been studied in the context of drug-resistant epilepsy (DRE). However, the rs2304725 polymorphism in SLC6A11 was not found to be significantly correlated with DRE in most genetic models, suggesting that while SLC6A11 may play a role in epilepsy, it may not be a major genetic risk factor for drug resistance in this condition (Hu2023Association).

Mutations in SLC6A11 can also lead to structural defects in the transporter protein, affecting its folding and trafficking. This can result in the protein being trapped in the endoplasmic reticulum, preventing its proper function and contributing to disease (Fischer2022Molecular). These findings highlight the clinical significance of SLC6A11 in neurological disorders and the potential for targeted therapeutic approaches.

## Interactions
The SLC6A11 gene encodes the GABA transporter 3 (GAT-3), which is involved in the regulation of neurotransmitter signaling by reuptaking GABA from synaptic clefts. GAT-3 is predominantly expressed in glial cells and plays a crucial role in modulating GABA signaling at synapses (Pramod2013SLC6). While specific protein interactions involving SLC6A11 are not extensively detailed, the regulatory mechanisms and interactions of related GABA transporters, such as GAT1, provide insights into potential interactions for GAT-3. 

GAT1, another GABA transporter, interacts with proteins like syntaxin 1A and Munc-18, which are involved in synaptic vesicle release and membrane trafficking (Ryan2021Regulation). These interactions suggest that GAT-3 may also participate in similar complexes or regulatory pathways, influencing its localization and function in the nervous system. Additionally, GAT3 is a target for anticonvulsant drugs, which are derivatives of nipecotic acid, indicating its involvement in therapeutic interactions (Pramod2013SLC6). 

Although specific interactions of GAT-3 with proteins or nucleic acids are not explicitly mentioned, the described regulatory mechanisms and protein interactions of related transporters may be relevant to understanding SLC6A11's interactions.


## References


[1. (Kristensen2011SLC6) Anders S. Kristensen, Jacob Andersen, Trine N. Jørgensen, Lena Sørensen, Jacob Eriksen, Claus J. Loland, Kristian Strømgaard, and Ulrik Gether. Slc6 neurotransmitter transporters: structure, function, and regulation. Pharmacological Reviews, 63(3):585–640, July 2011. URL: http://dx.doi.org/10.1124/pr.108.000869, doi:10.1124/pr.108.000869. This article has 679 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1124/pr.108.000869)

[2. (Zhou2013GABA) Yun Zhou and Niels Christian Danbolt. Gaba and glutamate transporters in brain. Frontiers in Endocrinology, 2013. URL: http://dx.doi.org/10.3389/fendo.2013.00165, doi:10.3389/fendo.2013.00165. This article has 270 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2013.00165)

[3. (Colas2020Toward) Claire Colas. Toward a systematic structural and functional annotation of solute carriers transporters—example of the slc6 and slc7 families. Frontiers in Pharmacology, August 2020. URL: http://dx.doi.org/10.3389/fphar.2020.01229, doi:10.3389/fphar.2020.01229. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2020.01229)

[4. (Fischer2022Molecular) Florian P. Fischer, Ameya S. Kasture, Thomas Hummel, and Sonja Sucic. Molecular and clinical repercussions of gaba transporter 1 variants gone amiss: links to epilepsy and developmental spectrum disorders. Frontiers in Molecular Biosciences, March 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.834498, doi:10.3389/fmolb.2022.834498. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.834498)

[5. (Pramod2013SLC6) Akula Bala Pramod, James Foster, Lucia Carvelli, and L. Keith Henry. Slc6 transporters: structure, function, regulation, disease association and therapeutics. Molecular Aspects of Medicine, 34(2–3):197–219, April 2013. URL: http://dx.doi.org/10.1016/j.mam.2012.07.002, doi:10.1016/j.mam.2012.07.002. This article has 233 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.mam.2012.07.002)

[6. (Eulenburg2010Neurotransmitter) Volker Eulenburg and Jesús Gomeza. Neurotransmitter transporters expressed in glial cells as regulators of synapse function. Brain Research Reviews, 63(1–2):103–112, May 2010. URL: http://dx.doi.org/10.1016/j.brainresrev.2010.01.003, doi:10.1016/j.brainresrev.2010.01.003. This article has 145 citations.](https://doi.org/10.1016/j.brainresrev.2010.01.003)

[7. (Ryan2021Regulation) Renae M. Ryan, Susan L. Ingram, and Annalisa Scimemi. Regulation of glutamate, gaba and dopamine transporter uptake, surface mobility and expression. Frontiers in Cellular Neuroscience, April 2021. URL: http://dx.doi.org/10.3389/fncel.2021.670346, doi:10.3389/fncel.2021.670346. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2021.670346)

[8. (Hu2023Association) Xuemei Hu, Mingyang Zhao, Xue Yang, Dongsen Wang, and Qingjian Wu. Association between the slc6a11 rs2304725 and gabrg2 rs211037 polymorphisms and drug-resistant epilepsy: a meta-analysis. Frontiers in Physiology, May 2023. URL: http://dx.doi.org/10.3389/fphys.2023.1191927, doi:10.3389/fphys.2023.1191927. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphys.2023.1191927)